525 related articles for article (PubMed ID: 19339934)
1. HIV-associated Hodgkin lymphoma.
Carbone A; Gloghini A; Serraino D; Spina M
Curr Opin HIV AIDS; 2009 Jan; 4(1):3-10. PubMed ID: 19339934
[TBL] [Abstract][Full Text] [Related]
2. AIDS-related malignancies: emerging challenges in the era of highly active antiretroviral therapy.
Cheung MC; Pantanowitz L; Dezube BJ
Oncologist; 2005; 10(6):412-26. PubMed ID: 15967835
[TBL] [Abstract][Full Text] [Related]
3. Prognostic factors for advanced-stage human immunodeficiency virus-associated classical Hodgkin lymphoma treated with doxorubicin, bleomycin, vinblastine, and dacarbazine plus combined antiretroviral therapy: a multi-institutional retrospective study.
Castillo JJ; Bower M; Brühlmann J; Novak U; Furrer H; Tanaka PY; Besson C; Montoto S; Cwynarski K; Abramson JS; Dalia S; Bibas M; Connors JM; Furman M; Nguyen ML; Cooley TP; Beltran BE; Collins JA; Vose JM; Xicoy B; Ribera JM;
Cancer; 2015 Feb; 121(3):423-31. PubMed ID: 25251326
[TBL] [Abstract][Full Text] [Related]
4. Population-based patterns of human immunodeficiency virus-related Hodgkin lymphoma in the Greater San Francisco Bay Area, 1988-1998.
Glaser SL; Clarke CA; Gulley ML; Craig FE; DiGiuseppe JA; Dorfman RF; Mann RB; Ambinder RF
Cancer; 2003 Jul; 98(2):300-9. PubMed ID: 12872349
[TBL] [Abstract][Full Text] [Related]
5. Advances in the management of HIV-related non-Hodgkin lymphoma.
Behler CM; Kaplan LD
Curr Opin Oncol; 2006 Sep; 18(5):437-43. PubMed ID: 16894290
[TBL] [Abstract][Full Text] [Related]
6. Excessive neurotoxicity with ABVD when combined with protease inhibitor-based antiretroviral therapy in the treatment of AIDS-related Hodgkin lymphoma.
Cheung MC; Hicks LK; Leitch HA
Clin Lymphoma Myeloma Leuk; 2010 Apr; 10(2):E22-5. PubMed ID: 20371439
[TBL] [Abstract][Full Text] [Related]
7. Human immunodeficiency and Hodgkin lymphoma.
Sissolak G; Sissolak D; Jacobs P
Transfus Apher Sci; 2010 Apr; 42(2):131-9. PubMed ID: 20138008
[TBL] [Abstract][Full Text] [Related]
8. Changing pattern of primary cerebral lymphoma in the highly active antiretroviral therapy era.
Cingolani A; Fratino L; Scoppettuolo G; Antinori A
J Neurovirol; 2005; 11 Suppl 3():38-44. PubMed ID: 16540454
[TBL] [Abstract][Full Text] [Related]
9. Lessons from clinical trials in African Burkitt lymphoma.
Magrath I
Curr Opin Oncol; 2009 Sep; 21(5):462-8. PubMed ID: 19620863
[TBL] [Abstract][Full Text] [Related]
10. Variant lymphoproliferative disorder of granular lymphocytes (LDGL) following Hodgkin lymphoma.
Jenkins BD; Snower D; Mohamed A; Al-Katib A
Am J Hematol; 2005 Jun; 79(2):128-31. PubMed ID: 15929104
[TBL] [Abstract][Full Text] [Related]
11. Current treatment strategies for patients with Hodgkin's lymphoma and HIV infection.
Hartmann P; Rehwald U; Salzberger B; Franzen C; Diehl V
Expert Rev Anticancer Ther; 2004 Jun; 4(3):401-10. PubMed ID: 15161439
[TBL] [Abstract][Full Text] [Related]
12. AIDS and non-Hodgkin's lymphoma. Experience at an oncological center in Mexico.
Cornejo-Juárez P; Volkow-Fernández P; Avilés-Salas A; Calderón-Flores E
Rev Invest Clin; 2008; 60(5):375-81. PubMed ID: 19227434
[TBL] [Abstract][Full Text] [Related]
13. Current status of the treatment of HIV-associated lymphoma.
Kaplan LD
Clin Adv Hematol Oncol; 2004 Jan; 2(1):28-9. PubMed ID: 16163156
[No Abstract] [Full Text] [Related]
14. Modern management of non-Hodgkin lymphoma in HIV-infected patients.
Mounier N; Spina M; Gisselbrecht C
Br J Haematol; 2007 Mar; 136(5):685-98. PubMed ID: 17229246
[TBL] [Abstract][Full Text] [Related]
15. Early versus late intensification for patients with high-risk Hodgkin lymphoma-3 cycles of intensive chemotherapy plus low-dose lymph node radiation therapy versus 4 cycles of combined doxorubicin, bleomycin, vinblastine, and dacarbazine plus myeloablative chemotherapy with autologous stem cell transplantation: five-year results of a randomized trial on behalf of the GOELAMS Group.
Arakelyan N; Berthou C; Desablens B; de Guibert S; Delwail V; Moles MP; Quittet P; Jais JP; Colonna P; Andrieu JM;
Cancer; 2008 Dec; 113(12):3323-30. PubMed ID: 18988286
[TBL] [Abstract][Full Text] [Related]
16. High Risk Features Contrast With Favorable Outcomes in HIV-associated Hodgkin Lymphoma in the Modern cART Era, ANRS CO16 LYMPHOVIR Cohort.
Besson C; Lancar R; Prevot S; Brice P; Meyohas MC; Marchou B; Gabarre J; Bonnet F; Goujard C; Lambotte O; Boué F; Mounier N; Partisani M; Raffi F; Costello R; Hendel-Chavez H; Algarte-Genin M; Trabelsi S; Marchand L; Raphael M; Taoufik Y; Costagliola D
Clin Infect Dis; 2015 Nov; 61(9):1469-75. PubMed ID: 26223997
[TBL] [Abstract][Full Text] [Related]
17. HIV-associated Hodgkin lymphoma: a clinicopathologic and immunophenotypic study of 45 cases.
Thompson LD; Fisher SI; Chu WS; Nelson A; Abbondanzo SL
Am J Clin Pathol; 2004 May; 121(5):727-38. PubMed ID: 15151213
[TBL] [Abstract][Full Text] [Related]
18. Cumulative HIV viremia during highly active antiretroviral therapy is a strong predictor of AIDS-related lymphoma.
Zoufaly A; Stellbrink HJ; Heiden MA; Kollan C; Hoffmann C; van Lunzen J; Hamouda O;
J Infect Dis; 2009 Jul; 200(1):79-87. PubMed ID: 19476437
[TBL] [Abstract][Full Text] [Related]
19. Update in HIV lymphoma.
Noy A
Curr Opin Oncol; 2006 Sep; 18(5):449-55. PubMed ID: 16894292
[TBL] [Abstract][Full Text] [Related]
20. Will BEACOPP be the standard for high risk Hodgkin lymphoma patients in advanced stages?
Diehl V; Fuchs M;
Transfus Apher Sci; 2007 Aug; 37(1):37-41. PubMed ID: 17714996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
